Miltenyi Biomedicine Gmbh
Clinical trials sponsored by Miltenyi Biomedicine Gmbh, explained in plain language.
-
New CAR t therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis study tests a new cell therapy (MB-CART2019.1) as an early, intensive treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after initial chemotherapy to see if it can keep the cancer from coming back. The main goal is to me…
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New stem cell graft technique aims to reduce transplant complications in blood cancer patients
Disease control Not yet recruitingThis study tests a new way to prepare stem cell grafts from half-matched donors for adults with high-risk blood cancers who lack a fully matched donor. The approach removes certain immune cells to lower the risk of severe graft-versus-host disease, a common and serious complicati…
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 11, 2026 20:47 UTC